New IC-10-PCS Codes

Why This Topic Matters

New ICD-10-PCS code additions can affect inpatient procedure reporting, documentation review, and coding accuracy for COVID-19 vaccine administration and therapeutic substance delivery. Staying aligned with these updates helps organizations reflect current procedures and avoid miscoding when new substances or vaccine scenarios are documented.

Article Sections

1. COVID-19 Vaccine Administration

   This section covers newly added ICD-10-PCS procedure codes associated with COVID-19 vaccine administration and discusses the broader clinical context for vaccine timing and documentation. It also notes the evolving guidance environment surrounding boosters and additional doses.

2. Introduction of New Therapeutic Substances

   This section describes new substance values added to an ICD-10-PCS table and the general category of therapeutic substance introductions they support. It introduces the substances and technology group context referenced by the update.

3. Fostamatinib

   This section addresses newly created procedure codes related to administration of fostamatinib and the setting in which it may be documented. It also mentions the broader clinical and regulatory context for this substance.

4. Tixagevimab and Cilgavimab

   This section covers the new code associated with administration of a monoclonal antibody combination and the related prophylaxis context. It also explains the general reporting scenario discussed for this treatment.

5. Other Monoclonal Antibody

   This section discusses a new code for other new monoclonal antibody treatments and the circumstances under which it may be relevant. It also notes the distinction from monoclonal antibody use for non-COVID-19 conditions.